MeiraGTx Receives Rare Pediatric Disease Designation for A002 for the Treatment of Achromatopsia Due to Mutations in the CNGB3 Gene

LONDON and NEW YORK, Feb. 1, 2018 /PRNewswire/ -- MeiraGTx, a London and New York-based gene therapy company, today announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the U.S. Food and Drug Administration (FDA) have granted rare pediatric disease...

from PR Newswire: //http://ift.tt/2DPQVGK